Cardio3 sets up US subsidiary to support C-Cure trials and approval
This article was originally published in Clinica
Belgian regenerative medicine specialist Cardio3 BioSciences has opened a US subsidiary to support US trials and approval of its lead product C-Cure, a stem cell therapy for heart failure. The subsidiary, in Rochester, Minnesota, will also help Cardio3 foster stronger ties with the Mayo Clinic, also based in Rochester, which developed the technology underlying C-Cure before licensing it to the company.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.